Supernus Late Saturday, Announced New Qelbree Data Showing Improvement In ADHD Symptoms
Portfolio Pulse from Charles Gross
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has announced new data showing improved efficacy in children and adults with ADHD when treated with Qelbree. The data, presented at Psych Congress 2023, shows that Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant medication in pediatric patients with ADHD. Additionally, long-term data show Qelbree consistently improved symptoms and executive function in adults with ADHD.
September 10, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The announcement of positive data for Qelbree by Supernus Pharmaceuticals could potentially boost investor confidence and have a positive impact on the company's stock in the short term.
The announcement of positive data for a company's product typically boosts investor confidence in the company, which can lead to an increase in the company's stock price. In this case, the positive data for Qelbree, a product of Supernus Pharmaceuticals, could potentially have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100